BB, Interesting speculation on your part. Of course, it may be that
NVS is only interested in Europe, and AMRN's delay in filing with
the EMA certainly looks suspicious of something else going on.
"If" AMRN is acquired I think the leading contenders would be NVS,
PFE, and AMGN. Still, I can't help but wonder if some sort of a
consortium is formed either as part of a buyout, or done after one
BP wins the contest to be the suitor of AMRN. Vascepa is potentially
too ubiquitous a medication for just one BP to distribute. One key
question is what is the most likely window for a deal to be agreed to.
Will they wait for the label expansion, or move beforehand? The FDA
knows how large a market Vascepa will have and how critical a role
it will play in the containment of future health care costs.
News 
Market Data 
Discover 
